12/20
11:10 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
12/20
10:50 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
12/20
10:50 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
12/16
10:03 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at William Blair.
12/16
10:03 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at William Blair.
12/16
08:30 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.
12/16
08:30 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.
12/16
08:23 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
12/16
08:23 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
12/16
08:06 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Medium
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
11/11
02:01 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/11
01:33 pm
nbix
Rating for NBIX
Low
Report
Rating for NBIX
11/11
01:33 pm
nbix
Rating for NBIX
Low
Report
Rating for NBIX
11/1
08:15 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
10/31
06:40 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
10/31
06:40 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
10/30
07:51 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
10/30
07:51 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
10/29
08:00 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
10/29
06:15 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
10/29
06:15 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
10/17
09:57 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
10/17
09:57 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
10/10
09:36 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $155.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $155.00 price target on the stock.
10/10
09:36 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $155.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $155.00 price target on the stock.